# Peloton Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peloton-therapeutics

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.pelotontherapeutics.com
- Total disclosed funding: $214M
- Latest round: Series E (Feb 14, 2019)
- Investors on record: 14

## About

Peloton Therapeutics, Inc. is a biotechnology company focused on developing innovative pharmaceutical therapies aimed at treating cancer and serious health conditions through targeted mechanisms.Founded in 2010 and headquartered in Dallas, US, Peloton Therapeutics, Inc. specializes in developing drugs that target HIF-2a, a crucial factor in certain cancers. The company has not undergone any reported changes in its operations and does not have any known subsidiaries. In May 2019, Peloton completed a TRADE SALE to Merck, raising USD 1.05 billion in cash, plus potential milestone payments totaling up to USD 1.15 billion. This transaction marks the culmination of efforts across 10 deals since its inception, with a total amount raised of USD 1.05 billion as of the latest round. The company’s founder has not been disclosed in available resources.Peloton Therapeutics, Inc. focuses on developing pharmaceutical products aimed at treating cancer, particularly renal cell carcinoma and von Hippel-Lindau (VHL) disease. Their primary candidates target and modulate HIF-2a activity, addressing significant unmet medical needs in oncology. The company’s products are directed towards healthcare providers, oncologists, and research institutions within the US, with plans for potential market expansion internationally as clinical trials progress.Peloton Therapeutics operates under a revenue model that relies on partnerships and collaborations within the pharmaceutical industry. Revenue is generated through milestone payments from collaborations with larger pharmaceutical firms and potential royalty agreements upon successful product commercialization. The company prioritizes structured agreements with healthcare organizations and research institutions, ensuring ongoing investment in clinical trials to validate its drug candidates. The pricing for their therapies is expected to align with industry standards for cancer treatments, reflecting the complexities involved in drug development.Peloton Therapeutics is focused on expanding its portfolio of products aimed at treating serious health conditions, particularly cancer therapies centered around HIF-2a. The funding from the recent TRADE SALE to Merck will support clinical trials and the development of new product candidates as they aim to enhance their therapeutic offerings. The company is also looking to broaden its market reach internationally, although specific regions and timelines for expansion have not been disclosed.

## Funding rounds

- Series E, Feb 14, 2019, $150M — OrbiMed Advisors, The Column Group, Topspin Partners, Nextech, Driehaus Capital Management, Tichenor Ventures, Foresite Capital, BVF Partners, RA Capital Management, EcoR1 Capital, Eventide Asset Management, Vida Ventures, Curative Ventures
- Series D, Sep 8, 2016, $15M — The Column Group, Topspin Partners, Nextech, Tichenor Ventures, Foresite Capital, Remeditex Ventures
- Series D, Apr 6, 2016, $38M — The Column Group, Topspin Partners, Nextech, Tichenor Ventures, Foresite Capital, Remeditex Ventures
- Series A, Sep 30, 2012, $9.7M — The Column Group
- Series A, Jul 13, 2011, $2M — The Column Group, Remeditex Ventures

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series D, Series E
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series A, Series D
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series D, Series E
- Nextech (https://capitalatlas.ai/funds/nextech) — Series D, Series E
- Tichenor Ventures — Series D, Series E
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series D, Series E
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series E
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series E
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series E
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series E
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series E
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series E
- Curative Ventures (https://capitalatlas.ai/funds/curative-ventures) — Series E